Jack Henry & Associates (JKHY) Shares Declined While Frontier Capital Management Co Lowered by $6.39 Million Its Stake; Timessquare Capital Management Trimmed Holding in Bio (BIO) by $8.20 Million

Bio-Rad Laboratories, Inc. (NYSE:BIO) Logo

Timessquare Capital Management Llc decreased its stake in Bio (BIO) by 4.8% based on its latest 2018Q3 regulatory filing with the SEC. Timessquare Capital Management Llc sold 26,297 shares as the company’s stock declined 18.28% with the market. The institutional investor held 521,985 shares of the capital goods company at the end of 2018Q3, valued at $163.38 million, down from 548,282 at the end of the previous reported quarter. Timessquare Capital Management Llc who had been investing in Bio for a number of months, seems to be less bullish one the $7.23B market cap company. The stock increased 0.23% or $0.55 during the last trading session, reaching $241.42. About 127,811 shares traded. Bio-Rad Laboratories, Inc. (NYSE:BIO) has declined 1.28% since January 12, 2018 and is downtrending. It has underperformed by 1.28% the S&P500. Some Historical BIO News: 16/03/2018 – Bio-Rad Labs: KPMG Needs More Time to Ccomplete Audit, Assessment of Effectiveness of Internal Control Over Reporting; 08/05/2018 – BIO-RAD 1Q EPS $21.77, EST. $1.040; 16/03/2018 – Bio-Rad Laboratories Cites Continuing Review, Audit by KPMG; 14/05/2018 – Clinton Group Adds Dominion Energy, Exits PPL, Cuts Bio-Rad: 13F; 08/05/2018 – Bio-Rad Laboratories 1Q EPS $21.77; 22/03/2018 – Bio-Rad Laboratories Receives Expected NYSE Notice Regarding Late Form 10-K Filing; 08/05/2018 – BIO RAD LABORATORIES – FOR 2018, CONTINUES TO ANTICIPATE CURRENCY-NEUTRAL REVENUE GROWTH OF APPROXIMATELY 3.5 TO 4.0 PERCENT; 16/03/2018 – BIO RAD LABORATORIES – CONCLUDED THAT INTERNAL CONTROL OVER FINANCIAL REPORTING WAS NOT EFFECTIVE AS OF DEC 31, 2017; 21/04/2018 – DJ Bio-Rad Laboratories Inc Class A, Inst Holders, 1Q 2018 (BIO); 16/03/2018 – BIO RAD LABORATORIES SAYS UNABLE TO FILE 2017 FORM 10-K BY EXTENDED FILING DEADLINE OF MARCH 16

Frontier Capital Management Co Llc decreased its stake in Jack Henry & Associates Inc. (JKHY) by 7.69% based on its latest 2018Q3 regulatory filing with the SEC. Frontier Capital Management Co Llc sold 39,953 shares as the company’s stock declined 15.66% with the market. The institutional investor held 479,340 shares of the technology company at the end of 2018Q3, valued at $76.73 million, down from 519,293 at the end of the previous reported quarter. Frontier Capital Management Co Llc who had been investing in Jack Henry & Associates Inc. for a number of months, seems to be less bullish one the $9.80B market cap company. The stock increased 0.48% or $0.6 during the last trading session, reaching $126.73. About 345,602 shares traded. Jack Henry & Associates, Inc. (NASDAQ:JKHY) has risen 15.38% since January 12, 2018 and is uptrending. It has outperformed by 15.38% the S&P500. Some Historical JKHY News: 03/05/2018 – Jack Henry & Associates Ranked Number 12 on America’s Best Employers List by Forbes

Since December 11, 2018, it had 0 insider buys, and 4 sales for $1.27 million activity. 1,411 shares were sold by TSINGOS CHRISTINE A, worth $349,928. Crowley Michael had sold 392 shares worth $97,228. TUMOLO ANNETTE had sold 2,376 shares worth $604,704 on Tuesday, December 11.

Timessquare Capital Management Llc, which manages about $20.35B and $15.09B US Long portfolio, upped its stake in Sp by 186,900 shares to 878,300 shares, valued at $84.35 million in 2018Q3, according to the filing. It also increased its holding in Rhythm Pharmaceuticals In by 75,300 shares in the quarter, for a total of 663,585 shares, and has risen its stake in Sunopta Inc (NASDAQ:STKL).

More notable recent Bio-Rad Laboratories, Inc. (NYSE:BIO) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare – Seeking Alpha” on September 05, 2018, also Cnbc.com with their article: “Opening Bell, November 13, 2018 – CNBC” published on November 13, 2018, Businesswire.com published: “Bio-Rad Quality Controls Now Available for Multiple Abbott Clinical Diagnostics Platforms – Business Wire” on December 03, 2018. More interesting news about Bio-Rad Laboratories, Inc. (NYSE:BIO) were released by: Seekingalpha.com and their article: “Positive Kadcyla data pressures Puma Bio, down 5% – Seeking Alpha” published on October 15, 2018 as well as Benzinga.com‘s news article titled: “Earnings Scheduled For August 7, 2018 – Benzinga” with publication date: August 07, 2018.

Among 8 analysts covering Bio-Rad Laboratories (NYSE:BIO), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Bio-Rad Laboratories had 26 analyst reports since August 7, 2015 according to SRatingsIntel. As per Friday, October 20, the company rating was maintained by Jefferies. The firm earned “Overweight” rating on Thursday, January 3 by Barclays Capital. Jefferies maintained the stock with “Buy” rating in Friday, April 28 report. The firm has “Buy” rating given on Thursday, June 8 by Jefferies. As per Wednesday, September 7, the company rating was maintained by Jefferies. The firm has “Neutral” rating given on Friday, February 16 by CL King. The firm has “Buy” rating given on Wednesday, June 28 by Deutsche Bank. C.L. King downgraded the shares of BIO in report on Friday, February 16 to “Hold” rating. The firm has “Buy” rating given on Thursday, July 13 by Jefferies. The stock has “Buy” rating by Jefferies on Wednesday, September 27.

Analysts await Bio-Rad Laboratories, Inc. (NYSE:BIO) to report earnings on February, 26. They expect $1.75 EPS, up 16.67% or $0.25 from last year’s $1.5 per share. BIO’s profit will be $52.37M for 34.49 P/E if the $1.75 EPS becomes a reality. After $0.91 actual EPS reported by Bio-Rad Laboratories, Inc. for the previous quarter, Wall Street now forecasts 92.31% EPS growth.

Investors sentiment increased to 1.07 in Q3 2018. Its up 0.02, from 1.05 in 2018Q2. It increased, as 19 investors sold BIO shares while 107 reduced holdings. 52 funds opened positions while 83 raised stakes. 17.73 million shares or 2.92% less from 18.26 million shares in 2018Q2 were reported. Asset Mngmt One stated it has 0% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Price T Rowe Associates Md reported 150,904 shares stake. Architects Incorporated holds 0% in Bio-Rad Laboratories, Inc. (NYSE:BIO) or 6 shares. State Treasurer State Of Michigan holds 0.02% or 7,400 shares. Canada Pension Plan Invest Board reported 125,900 shares. Jefferies Grp Inc Ltd invested in 2,258 shares. Teachers Retirement System Of The State Of Kentucky invested in 0.15% or 39,305 shares. Panagora Asset holds 0% or 1,217 shares in its portfolio. Bank Of America Corporation De reported 332,840 shares or 0.02% of all its holdings. Manufacturers Life Ins The stated it has 0.06% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Dorsey Wright & Assocs has invested 1.34% in Bio-Rad Laboratories, Inc. (NYSE:BIO). First Manhattan reported 599 shares. Deutsche Comml Bank Ag holds 0.01% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 60,183 shares. Trustmark State Bank Trust Department invested in 170 shares. Goldman Sachs Group Incorporated invested in 0.02% or 220,870 shares.

More notable recent Jack Henry & Associates, Inc. (NASDAQ:JKHY) news were published by: Nasdaq.com which released: “Jack Henry’s (JKHY) Earnings & Revenues Beat Estimates in Q4 – Nasdaq” on August 24, 2018, also Streetinsider.com with their article: “Jack Henry & Associates (JKHY) Set to Join S&P 500; EQT, Equitrans Midstream (ETRN), MasTec (MTZ) to Join S&P MidCap 400; Superior Energy Services (SPN), United Natural Foods (UNFI) to Join S&P SmallC – StreetInsider.com” published on November 07, 2018, Seekingalpha.com published: “Jack Henry & Associates declares $0.37 dividend – Seeking Alpha” on November 15, 2018. More interesting news about Jack Henry & Associates, Inc. (NASDAQ:JKHY) were released by: Seekingalpha.com and their article: “Jack Henry & Associates: Waiting For The Right Price – Seeking Alpha” published on September 11, 2017 as well as Seekingalpha.com‘s news article titled: “Jack Henry & Associates, Inc. (JKHY) CEO David Foss on Q1 2019 Results – Earnings Call Transcript – Seeking Alpha” with publication date: November 07, 2018.

Among 8 analysts covering Jack Henry (NASDAQ:JKHY), 1 have Buy rating, 0 Sell and 7 Hold. Therefore 13% are positive. Jack Henry had 21 analyst reports since August 27, 2015 according to SRatingsIntel. The rating was upgraded by Evercore on Wednesday, December 6 to “In-Line”. Robert W. Baird maintained Jack Henry & Associates, Inc. (NASDAQ:JKHY) rating on Tuesday, October 10. Robert W. Baird has “Neutral” rating and $108 target. On Wednesday, August 16 the stock rating was maintained by RBC Capital Markets with “Hold”. Cantor Fitzgerald maintained Jack Henry & Associates, Inc. (NASDAQ:JKHY) on Thursday, June 7 with “Overweight” rating. RBC Capital Markets maintained Jack Henry & Associates, Inc. (NASDAQ:JKHY) rating on Thursday, August 27. RBC Capital Markets has “Sector Perform” rating and $70 target. Robert W. Baird maintained the stock with “Hold” rating in Sunday, September 17 report. The stock of Jack Henry & Associates, Inc. (NASDAQ:JKHY) earned “Hold” rating by Oppenheimer on Tuesday, August 15. The firm has “Neutral” rating by Robert W. Baird given on Monday, July 16. The company was maintained on Thursday, November 9 by RBC Capital Markets. The stock has “Overweight” rating by Cantor Fitzgerald on Thursday, August 23.

Frontier Capital Management Co Llc, which manages about $15.53 billion US Long portfolio, upped its stake in Bright Horizons Family Solutions Inc. (NYSE:BFAM) by 35,681 shares to 524,252 shares, valued at $61.78 million in 2018Q3, according to the filing. It also increased its holding in Nektar Therapeutics (NASDAQ:NKTR) by 205,891 shares in the quarter, for a total of 1.30M shares, and has risen its stake in Interface Inc. (NASDAQ:TILE).

Since August 31, 2018, it had 0 insider purchases, and 2 sales for $1.40 million activity. On Tuesday, December 4 Forbis Mark S sold $404,727 worth of Jack Henry & Associates, Inc. (NASDAQ:JKHY) or 3,000 shares.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Institutional Positions Chart